[go: up one dir, main page]

MX2012006741A - Tratamiento para la enfermedad inflamatoria del intestino. - Google Patents

Tratamiento para la enfermedad inflamatoria del intestino.

Info

Publication number
MX2012006741A
MX2012006741A MX2012006741A MX2012006741A MX2012006741A MX 2012006741 A MX2012006741 A MX 2012006741A MX 2012006741 A MX2012006741 A MX 2012006741A MX 2012006741 A MX2012006741 A MX 2012006741A MX 2012006741 A MX2012006741 A MX 2012006741A
Authority
MX
Mexico
Prior art keywords
treatment
inflammatory bowel
bowel disease
methanone
indol
Prior art date
Application number
MX2012006741A
Other languages
English (en)
Inventor
Yong Mi Choi-Sledeski
Anne Minnich
Eszter Bekasi
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of MX2012006741A publication Critical patent/MX2012006741A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se divulga un tratamiento para la enfermedad inflamatoria del intestino, que usa un compuesto: como [4-(5-aminometil-2-fluorofen il)piperidin-1-il][7-fluoro-1-(2-metoxietil)-4-trifluorometoxi-1H -indol-3-il]metanona.
MX2012006741A 2009-12-23 2010-12-13 Tratamiento para la enfermedad inflamatoria del intestino. MX2012006741A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28959609P 2009-12-23 2009-12-23
FR1057198 2010-09-10
PCT/US2010/060002 WO2011078983A1 (en) 2009-12-23 2010-12-13 Treatment for inflammatory bowel disease

Publications (1)

Publication Number Publication Date
MX2012006741A true MX2012006741A (es) 2012-07-04

Family

ID=44246889

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012006741A MX2012006741A (es) 2009-12-23 2010-12-13 Tratamiento para la enfermedad inflamatoria del intestino.

Country Status (14)

Country Link
US (1) US20120238603A1 (es)
EP (1) EP2515851A1 (es)
JP (1) JP2013515723A (es)
KR (1) KR20120107999A (es)
CN (1) CN102753144A (es)
AR (1) AR079779A1 (es)
AU (1) AU2010333892A1 (es)
CA (1) CA2785434A1 (es)
MX (1) MX2012006741A (es)
RU (1) RU2012131327A (es)
SG (1) SG181592A1 (es)
TW (1) TW201141475A (es)
UY (1) UY33135A (es)
WO (1) WO2011078983A1 (es)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9923710D0 (en) * 1999-10-08 1999-12-08 Proteus Molecular Design Chemical compounds
AR033525A1 (es) * 2000-05-22 2003-12-26 Aventis Pharma Ltd Arilmetilaminas sustituidas, composiciones farmaceuticas, uso de las mismas para la manufactura de un medicamento
EP1571150A1 (en) * 2004-03-02 2005-09-07 Aventis Pharma Deutschland GmbH Process for the preparation of tryptase inhibitors
DOP2005000039A (es) * 2004-03-26 2005-10-31 Aventis Pharma Inc Hidrocloruro de [4-(5-aminometil-2-fluoro-fenil)- piperidin-1-il]-(4-bomo-3-metil-5-propoxi-tiofen-2-il)-metanona como un inhibidor de la triptasa de mastocitos
JP2011504499A (ja) * 2007-11-21 2011-02-10 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ トリプターゼ阻害剤として使用するためのスピロピペリジン
HRP20151338T1 (hr) * 2008-08-22 2016-01-15 Sanofi [4-(5-aminometil-2-fluoro-fenil)-piperidin-1-il]-[7-fluoro-1-(2-metoksi-etil)-4trifluorometoksi-1h-indol-3-il]metanon kao inhibitor triptaze mastocita

Also Published As

Publication number Publication date
JP2013515723A (ja) 2013-05-09
EP2515851A1 (en) 2012-10-31
UY33135A (es) 2011-07-29
CA2785434A1 (en) 2011-06-30
US20120238603A1 (en) 2012-09-20
SG181592A1 (en) 2012-07-30
KR20120107999A (ko) 2012-10-04
AU2010333892A1 (en) 2012-07-19
AR079779A1 (es) 2012-02-22
CN102753144A (zh) 2012-10-24
TW201141475A (en) 2011-12-01
RU2012131327A (ru) 2014-02-10
WO2011078983A1 (en) 2011-06-30

Similar Documents

Publication Publication Date Title
GEP20135898B (en) Rifaximin forms and usage
PT2252148T (pt) Métodos de tratamento da síndrome do intestino irritável
MX301000B (es) Produccion de etanol en microorganismos.
AP2011005817A0 (en) Substituted piperidines as CCR3 antagonists.
UA104203C2 (en) Microbiocidal heterocycles
SG148142A1 (en) Aryloazol-2-yl cyanoethylamino compunds, method of making and method of using thereof
AP2010005364A0 (en) Novel heterocyclic compounds.
ZA201102315B (en) 7-piperidinoalkyl-3,4-dihyfroquinolone derivative
ZA201201653B (en) Novel azaheterocyclic compounds
IL217950A0 (en) N1-substituted-5-fluoro-2-oxopyrimidinone-1(2h)-carboxamide derivatives
PT2462133E (pt) Derivados 5-fluoro-2-oxopirimidina-1(2h)-carboxilato
IL213983A0 (en) Heteroaryl substituted pyridazinone derivatives
PT2437739E (pt) Tratamento de glomerulonefrite
UA104867C2 (uk) Похідні феноксихроманкарбонової кислоти, заміщені в 6-ому положенні
IN2012DN03846A (es)
ZA200805756B (en) 4-(3-benzoylaminophenyl)-6,7-dimethoxy-2-methylaminoquinazoline derivative
MX2009010903A (es) Metodos para preparar compuestos basados en imidazol.
SI2281801T1 (sl) Postopek za pridobivanje 3,3-diphenilpropilamina
GB201210680D0 (en) Vaginal, speculum
IL211062A0 (en) Pharmaceutical uses of lanosta-8,24-dien-3-ols
MX2012006741A (es) Tratamiento para la enfermedad inflamatoria del intestino.
MD4009C2 (ro) Utilizarea 1-metil-4-(N-metilaminobutil-4)-β-carbolinei în calitate de remediu antituberculos
MX2012009523A (es) Tratamiento de afecciones alergicas dermatologicas.
UA41721U (uk) 1-дезокси-1-n-метиламонію-d-глюцитолу сукцинат
UA102670C2 (ru) Производные пиридопиримидиндионов для лечения опосредованного pde 4 болезненного состояния

Legal Events

Date Code Title Description
FA Abandonment or withdrawal